Immunotherapy: The Development of Immunotherapy in Urothelial Bladder Cancer

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2015 Mar 18

PMID 25781573

Citations 4

Authors

Tom Powles

Affiliations

Soon will be listed here.

Citing Articles

Development and validation of an intra-tumor heterogeneity-related signature to predict prognosis of bladder cancer: a study based on single-cell RNA-seq.

Zhou R, Liang J, Chen Q, Tian H, Yang C, Liu C Aging (Albany NY). 2021; 13(15):19415-19441.

PMID: 34339395 PMC: 8386527. DOI: 10.18632/aging.203353.

Coming of Age of Immunotherapy of Urothelial Cancer.

Grande E, Molina-Cerrillo J, Necchi A Target Oncol. 2021; 16(3):283-294.

PMID: 33710533 DOI: 10.1007/s11523-021-00804-7.

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

Massard C, Gordon M, Sharma S, Rafii S, Wainberg Z, Luke J J Clin Oncol. 2016; 34(26):3119-25.

PMID: 27269937 PMC: 5569690. DOI: 10.1200/JCO.2016.67.9761.

Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies.

Choudhury N, Nakamura Y Cancer Sci. 2015; 107(2):107-15.

PMID: 26678880 PMC: 4768396. DOI: 10.1111/cas.12862.

References

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Choueiri T, Figueroa D, Fay A, Signoretti S, Liu Y, Gagnon R . Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res. 2014; 21(5):1071-7. DOI: 10.1158/1078-0432.CCR-14-1993. View

Witjes J, Comperat E, Cowan N, De Santis M, Gakis G, Lebret T . EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2013; 65(4):778-92. DOI: 10.1016/j.eururo.2013.11.046. View

. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507(7492):315-22. PMC: 3962515. DOI: 10.1038/nature12965. View

Powles T, Eder J, Fine G, Braiteh F, Loriot Y, Cruz C . MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515(7528):558-62. DOI: 10.1038/nature13904. View